Jpmorgan Chase & CO Alector, Inc. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Alector, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,715,764 shares of ALEC stock, worth $7.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,715,764

Previous 1,863,998 7.95%

Holding current value

$7.79 Million

Previous $14.9 Million 30.56%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$5.69 - $8.08 $843,451 - $1.2 Million	-148,234 Reduced 7.95%	1,715,764 $10.3 Million
Q4 2023 Feb 12, 2024	SELL	$3.77 - $8.39 $1.6 Million - $3.56 Million	-424,371 Reduced 18.54%	1,863,998 $14.9 Million
Q3 2023 Nov 14, 2023	SELL	$5.2 - $8.77 $549,614 - $926,945	-105,695 Reduced 4.41%	2,288,369 $14.8 Million
Q2 2023 Aug 11, 2023	BUY	$5.86 - $7.93 $70,800 - $95,810	12,082 Added 0.51%	2,394,064 $14.4 Million
Q1 2023 May 18, 2023	BUY	$5.85 - $9.84 $454,036 - $763,711	77,613 Added 3.37%	2,381,982 $14.7 Million

Q1 2023 May 11, 2023	SELL	$5.85 - $9.84 $678,161 - $1.14 Million	-115,925 Reduced 4.79%	2,304,369 $14.3 Million
Q4 2022 Feb 13, 2023	BUY	$6.88 - $9.55 $249,076 - $345,738	36,203 Added 1.52%	2,420,294 $22.3 Million
Q3 2022 Nov 14, 2022	SELL	$8.19 - $13.2 $743,635 - $1.2 Million	-90,798 Reduced 3.67%	2,384,091 $22.6 Million
Q2 2022 Aug 11, 2022	BUY	$7.65 - $14.24 $147,813 - $275,145	19,322 Added 0.79%	2,474,889 $25.1 Million
Q1 2022 May 11, 2022	SELL	$13.02 - $20.78 $925,305 - $1.48 Million	-71,068 Reduced 2.81%	2,455,567 $35 Million
Q4 2021 Feb 10, 2022	SELL	$19.35 - $25.54 $643,542 - $849,409	-33,258 Reduced 1.3%	2,526,635 $52.2 Million
Q3 2021 Nov 12, 2021	BUY	$21.65 - $39.49 $55.4 Million - $101 Million	2,559,893 New	2,559,893 $58.4 Million

Others Institutions Holding ALEC

# of Institutions

161

Shares Held

59.8M

Call Options Held

67.8K

Put Options Held

200

View Full List

About Alector, Inc.

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $375M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

More about ALEC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Alector, Inc. Transaction History